August 9, 2022 Dataset Open Access

Moldovan, Rares-Petru; Gündel, Daniel; Deuther-Conrad, Winnie; Ueberham, Lea; Kaur, Sarandeep; Otikova, Elina; Teodoro, Rodrigo; Lai, Thu Hang; Clauß, Oliver; Scheunemann, Matthias; Bormans, Guy; Kopka, Klaus; Bachmann, Michael; Brust, Peter

Citation Style Language JSON Export

{
  "id": "1381", 
  "type": "dataset", 
  "title": "Data Publication: Structure-Based Design, Optimization and Development of [18F]LU13, a novel radioligand for CB2R Imaging in the Brain with PET", 
  "DOI": "10.14278/rodare.1381", 
  "publisher": "Rodare", 
  "author": [
    {
      "family": "Moldovan, Rares-Petru"
    }, 
    {
      "family": "G\u00fcndel, Daniel"
    }, 
    {
      "family": "Deuther-Conrad, Winnie"
    }, 
    {
      "family": "Ueberham, Lea"
    }, 
    {
      "family": "Kaur, Sarandeep"
    }, 
    {
      "family": "Otikova, Elina"
    }, 
    {
      "family": "Teodoro, Rodrigo"
    }, 
    {
      "family": "Lai, Thu Hang"
    }, 
    {
      "family": "Clau\u00df, Oliver"
    }, 
    {
      "family": "Scheunemann, Matthias"
    }, 
    {
      "family": "Bormans, Guy"
    }, 
    {
      "family": "Kopka, Klaus"
    }, 
    {
      "family": "Bachmann, Michael"
    }, 
    {
      "family": "Brust, Peter"
    }
  ], 
  "issued": {
    "date-parts": [
      [
        2022, 
        8, 
        9
      ]
    ]
  }, 
  "abstract": "<p>The cannabinoid receptor type 2 (CB2R) is an attractive target for diagnosis and therapy of neurodegenerative diseases and cancer. Recently, we reported a novel naphthyrid-2-one based positron-emission tomography (PET) radioligand for imaging of the CB2R in the brain (<strong>[<sup>18</sup>F]5</strong>). In this study we aimed at the development of a novel <sup>18</sup>F-labeled CB2R radioligand with improved binding properties and metabolic stability. Starting from the structure of <strong>5</strong>, we developed a novel series of fluorinated derivatives by modifying the substituents at the naphthyrid-2-one subunit. Compound <strong>28</strong> (<strong>LU13</strong>) was identified with the highest binding affinity and selectivity versus CB1R (CB2R<em>K</em><sub>i</sub> = 0.6 nM; CB1R<em>K</em><sub>i</sub>/CB2R<em>K</em><sub>i</sub> &gt; 1000) and was selected for radiolabeling with <sup>18</sup>F and biological characterization. The radiofluorination was performed starting from the corresponding bromo-precursor (<strong>31</strong>) bearing a fully deuterated <em>N</em>-alkyl chain to protect against defluorination. The in vitro evaluation of <strong>[<sup>18</sup>F]LU13 </strong>proved the high binding affinity of the radioligand towards rat (rCB2R<em>K</em><sub>D</sub> = 0.2 nM) and human (hCB2R<em>K</em><sub>D</sub> = 1.1 nM) CB2R. Metabolism studies in mice revealed a metabolic stability at 30 min p.i. with fractions of parent compound of &gt;80% in the brain and 90% in the spleen with only trace of defluorination products detected in plasma. PET imaging in a rat model of vector-based/related overexpression in the striatum revealed a high signal to background ratio, demonstrating the ability of <strong>[<sup>18</sup>F]LU13</strong> to reach and selectively label the hCB2R in the brain. Thus, <strong>[<sup>18</sup>F]LU13 </strong>is a novel and highly promising PET radioligand for the imaging of up regulated CB2R expression under pathological conditions in the brain.</p>"
}